Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

Summary

This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.

Eligibility

Inclusion Criteria:

* Women and men ≥18 and ≤65 years of age
* Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
* Routinely treated and monitored for MS
* Speak and read Danish
* Deemed physically and mentally able to participate in this study

Exclusion Criteria:

* Active malignancy
* Diagnosis of Crohn's disease and ulcerative colitis
* Other comorbidities deemed to be relevant
* Haematopoietic stem cell transplantation
* Current or past treatment with non-MS related treatments deemed to be relevant
* Pregnancy or lactation
* People with MR contraindications:

  * Severe claustrophobia
  * Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations

Conditions2

Browse More Trials